Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING)
Publication date: 2026 Source: Cancer Treatment and Research Communications, Volume 49 Author(s): George Papaxoinis, Joseph Sgouros, Nikolaos Korfiatis, Kyriaki Papadopoulou, Amanda Psyrri, Georgios Zarkavelis, Alexandros Ioannou, Georgios Petrakis, Ioannis Kotsantis, Anna Koumarianou, Elena Fountzilas, Flora Zagouri, Epaminondas Samantas, George Fountzilas, George Pentheroudakis
Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING). // Cancer Treatment and Research Communications. – URL: https://www.sciencedirect.com/science/article/pii/S2468294226003904?dgcid=rss_sd_all
Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING). Cancer Treatment and Research Communications. https://www.sciencedirect.com/science/article/pii/S2468294226003904?dgcid=rss_sd_all
“Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING).” Cancer Treatment and Research Communications.
@article{article39847,
title = {Phase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING)},
journal = {Cancer Treatment and Research Communications},
url = {https://www.sciencedirect.com/science/article/pii/S2468294226003904?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment